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Abstract: Combination therapy is an effective strategy to increase antihypertensive efficacy 
in those patients with poor blood pressure (BP) control. In order to achieve BP targets, at least 
75% of patients may require combination therapy, and European guidelines advocate this 
approach, particularly in those patients with a high cardiovascular risk. Evidence from large, 
randomized controlled trials, and the European hypertension treatment guidelines is supportive 
of the use of an angiotensin receptor blocker (ARB) with a calcium channel blocker (CCB). 
Fixed-dose combination formulations of olmesartan medoxomil, an ARB, and the CCB amlo-
dipine are approved in several European countries for patients with essential hypertension. 
The olmesartan/amlodipine combination has demonstrated greater efficacy than its component 
monotherapies in reducing BP in patients with mild-to-severe hypertension. Significantly 
greater reductions in seated diastolic BP were observed between baseline and after eight weeks 
of treatment with olmesartan/amlodipine, compared with equivalent doses of olmesartan or 
amolodipine monotherapy (P , 0.001), in the factorial Combination of Olmesartan Medoxomil 
and Amlodipine Besylate in Controlling High Blood Pressure (COACH) trial. About 85% of 
the maximal BP reductions after the 8-week treatment period were already observed after two 
weeks. Uptitration as necessary, with or without hydrochlorothiazide, allowed the majority 
of patients to achieve BP control in a 44-week open-label extension treatment period to the 
COACH trial. The use of olmesartan/amlodipine allowed up to 54% of patients, with previously 
inadequate responses to amlodipine or olmesartan monotherapy, to achieve their BP goals. Data 
from post-registration studies using tight BP control and forced titration regimens have further 
demonstrated the high efficacy of olmesartan/amlodipine in achieving BP goal rates. Moreover, 
consistent reductions in BP were observed over the 24-hour dosing interval using ambulatory 
measurements. Olmesartan/amlodipine was generally well tolerated over the short- and long-
term, with a lower frequency of peripheral edema with olmesartan/amlodipine 40/10 mg than 
with amlodipine 10 mg monotherapy.
Keywords: hypertension, combination therapy, BP control, BP goals, antihypertensive 
monotherapy, patients
Introduction
Arterial hypertension is the single largest contributor to global mortality,1 and is 
responsible for approximately 7.1 million deaths each year.2 In 2000, it was estimated 
that nearly 1 billion people worldwide had hypertension, and it was predicted that the 
prevalence would increase to over 1.5 billion by 2025.3 The prevalence of hyperten-
sion among people aged 35–64 years is about 30% in the US population,4 and about 
44% in European countries.5 Hypertension continues to be underdiagnosed and 
undertreated.6Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Raised blood pressure (BP) is a major risk factor for 
stroke, heart disease and renal failure.7–9 Many clinical tri-
als have shown that BP reduction by a variety of strategies 
reduces the risk of stroke by approximately 35%, congestive 
heart failure by 42%, and coronary heart disease by 28%.10–14 
Current European guidelines recommend a target systolic BP 
(SBP) and diastolic BP (DBP) of ,140/90 mmHg in the gen-
eral population.9 However, despite these   recommendations 
and the well-documented relationship between hyperten-
sion and the increased cardiovascular (CV) and renal risk, 
BP control rates remain poor, particularly in Europe.15,16 
  Therefore, the primary aim of an effective antihypertensive 
treatment strategy is to lower elevated BP to target levels 
and to achieve a maximum reduction in risk. The recent 
reappraisal of the European guidelines on hypertension 
management recommends that it may be prudent to lower 
BP to values within the range of 130–139/80–85 mmHg in 
the majority of hypertensive patients, including those with 
diabetes.9 In these guidelines, both angiotensin receptor 
blockers (ARBs) and calcium channel blockers (CCBs) are 
recommended for first-line therapy either as monotherapy 
or in combination. This article reviews the rationale for 
fixed-dose combination therapy with the ARB olmesartan 
medoxomil and the CCB amlodipine.
Fixed-dose combination therapy  
versus monotherapy
Among the many factors that may contribute to suboptimal 
BP control rates are nonadherence of patients to therapy 
and clinical inertia, where physicians fail to increase the 
dosage of existing antihypertensive medication or prescribe 
combinations of antihypertensive drugs when patients do 
not achieve their BP goal.17–19 Increasing the dose of a single 
antihypertensive agent in an attempt to achieve an adequate 
response may lead, however, to an increase in side-effects, 
which can lead to noncompliance and exacerbation of the 
BP control problem. Hypertension is a complex multifacto-
rial condition comprising multiple pathways involved in BP 
control.20 The rationale behind combination therapy, using 
two or more drugs with different and complementary mecha-
nisms of action, is the potential to improve BP control by the 
combined effects and, by allowing lower doses of the drugs, 
to reduce unwanted side-effects.21 A recent meta-analysis 
of 10,968 patients from 42 trials has shown that the average 
antihypertensive effect of combining two drugs from differ-
ent classes (thiazides, beta-blockers, angiotensin-converting 
enzyme inhibitors [ACEIs] and CCBs) is approximately 
additive.22 The authors estimated that the additional reduc-
tion in BP produced by combining two drugs from differ-
ent classes was approximately five times greater than that 
achieved by doubling the dosage of either drug. Therefore, 
combination therapy is a simple and effective strategy to 
increase antihypertensive efficacy and, therefore, control BP 
in hypertensive patients.
In the past, monotherapy has been the standard initial 
treatment approach in most patients with hypertension, with 
combination therapy being initiated when stepwise increases 
in the dose of the single agent fail to achieve the required 
BP reduction. More recently, a number of clinical trials have 
clearly demonstrated that most patients receiving antihy-
pertensive combination therapy are indeed able to achieve 
adequate BP control.23–26 The available data suggest that, 
overall, at least 75% of patients with hypertension will require 
combination therapy to achieve BP targets.27 Accordingly, 
recent European treatment guidelines recommend the use 
of combination therapy as an alternative to monotherapy as 
initial treatment, particularly in patients at high CV risk.9
Single-pill combinations of two antihypertensive drugs, 
known as fixed-dose combinations, are now widely available, 
often combining an ACEI or an ARB as agents that target 
the renin–angiotensin system (RAS) with either a thiazide 
diuretic or a CCB.28,29 At low doses, fixed-dose combina-
tions may have greater efficacy and better tolerability than 
the respective high-dose monotherapies.29 Fixed-dose com-
binations can simplify the treatment schedule and improve 
compliance and persistence with therapy compared with two 
antihypertensive drugs given separately.30 It is reasonable to 
expect that this may result in improvements in BP control 
and reduction in the incidence of CV events. Importantly, 
combination antihypertensive therapy comprising either an 
ACEI or ARB is favorable since, unlike drugs from other 
classes, these agents can be used at higher doses to increase 
efficacy without compromising tolerability.31 Consequently, 
this poses the question of “what should be combined with 
a RAS blocker?”
Studies have shown that combination therapy with an 
ACEI (benazepril) and a CCB (amlodipine) provides supe-
rior BP-lowering efficacy compared with either agent as 
monotherapy.32,33 Subsequently, the ACCOMPLISH (Avoid-
ing Cardiovascular Events through Combination Therapy in 
Patients Living with Systolic Hypertension) trial was one 
of the first major studies to investigate the effects of fixed 
dose combination therapy and demonstrated the benefits 
of combination treatment comprising a RAS blocker/CCB 
and RAS blocker/thiazide diuretic by the achievement of 
very high levels of BP control. In this large, randomized, Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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double-blind clinical trial, the effects of benazepril plus 
amlodipine were compared with those of benazepril plus the 
thiazide diuretic hydrochlorothiazide (HCTZ) in   reducing 
CV morbidity and mortality in approximately 11,500 
patients at high risk of CV events.24 The study drugs were 
taken as a single-capsule formulation. Drug doses were 
force-titrated to attain recommended BP goals. BP con-
trol (,140/90 mmHg) was achieved by 75.4% of patients 
  receiving benazepril/amlodipine and 72.4% of patients 
receiving benazepril/HCTZ. Notably, the primary composite 
endpoint, including death from CV causes and CV events, 
were significantly (P , 0.001) reduced by approximately 
20% in the benazepril/amlodipine arm compared with the 
benazepril/HCTZ arm. However, these results should not 
be extrapolated to the general hypertensive population in 
regard to assuming that a RAS blocker/CCB combination is 
per se superior to a RAS blocker/thiazide diuretic combina-
tion since the patient population in ACCOMPLISH was not 
typical of the general hypertensive population: there was a 
high level of obesity and approximately 60% of patients were 
diabetic. Nonetheless, the combination of a RAS blocker 
plus a CCB was undoubtedly an effective combination in 
these patients, and supports the use of combination therapy 
comprising a RAS blocker and CCB to control BP and 
reduce CV risk in patients with hypertension, especially 
those with features of the metabolic syndrome such as 
obesity and diabetes.
Another randomized trial, ONTARGET (Ongoing Telm-
isartan Alone and in Combination with Ramipril Global 
Endpoint Trial), demonstrated that the ARB telmisartan was 
equally as effective as the ACEI ramipril in reducing the 
incidence of CV events in high-risk patients.34 Importantly, 
there was a lower incidence of cough and angio-edema in 
patients who received telmisartan compared with those who 
received ramipril. This result is consistent with a large-
scale observational study of more than 195,000 patients in 
the US Veterans Affairs Health Care System who initiated 
ACE therapy. The study found an increase in the incidence 
of angioedema associated with the use of ACEIs (1.97 
cases/1000 person years) compared with other antihyper-
tensive medications (0.51 cases/1000 person years), and that 
the risk of angioedema remained elevated with longer-term 
use, even beyond one year.35 Taken together these findings 
support the rationale for combining an ARB and a CCB as 
an antihypertensive strategy. This notion is reflected by the 
recent European hypertension treatment guidelines in which 
combination therapy with an ARB or ACEI plus a CCB is 
indeed a recommended strategy.9,36
Olmesartan/amlodipine combination  
therapy
Since ARBs inhibit the activity of the RAS by blocking the 
angiotensin II type 1 (AT1) receptor, the efficacy of the ARBs 
depend upon their ability to inhibit AT1 receptor activation 
by angiotensin II. Pharmacodynamic studies have shown that 
ARBs, when given in their recommended doses, differ in their 
ability to block the AT1 receptor. These differences in AT1 
receptor blockade may translate into differences between 
ARBs in their ability to control BP over 24 hours. This is in 
line with an independent meta-analysis of studies which used 
ambulatory BP monitoring (ABPM) to measure 24-hour BP 
control with ARBs. This meta-analysis found that the size of 
reduction in ambulatory SBP depended upon the drug used, 
and that the dose used affected the duration of the antihyper-
tensive activity for both systolic and diastolic BP.37
In this regard, the ARB olmesartan medoxomil (hereaf-
ter referred to as olmesartan) is of interest since it has been 
shown in pharmacodynamic studies to produce a strong level 
of AT1 receptor blockade in relation to dose.38–40 Furthermore, 
direct comparison with several other ARBs has shown that 
olmesartan produces robust antihypertensive efficacy over 
24 hours, the daytime, night-time, and end-of-dosing interval 
periods relative to losartan, candesartan or valsartan mono-
therapy, and was at least as efficacious as irbesartan.41–43
Clinical data suggest that olmesartan may protect against 
end-organ damage and, in this regard, renoprotective and 
anti-atherosclerotic effects have been reported in clinical and 
experimental studies. As with other members of this drug 
class, olmesartan has shown excellent, placebo-like toler-
ability in clinical studies.44 Taken together, the efficacy and 
excellent tolerability of olmesartan make it highly suitable 
for use in combination therapy.
Fixed-dose combination formulations of olmesartan and 
amlodipine (olmesartan/amlodipine 20/5 mg, 40/5 mg or 
40/10 mg) are approved in several European countries for 
once-daily administration in patients with essential hyper-
tension who have responded inadequately to either drug as 
monotherapy, or who are receiving separate tablets as combi-
nation therapy. Like olmesartan, amlodipine provides effec-
tive BP control and exhibits organ-protective properties.45
Therapeutic efficacy of olmesartan/ 
amlodipine
The efficacy of olmesartan/amlodipine has been evaluated 
in three key randomized, double-blind trials. The factorial 
Combination of Olmesartan Medoxomil and Amlodipine 
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trial evaluated the efficacy of dual combination therapy with 
olmesartan/amlodipine compared with its component mono-
therapies in patients with mild-to-severe hypertension.46–48 
Two add-on trials evaluated the efficacy of olmesartan plus 
amlodipine in patients with moderate-to-severe hypertension 
who responded inadequately to amlodipine49 or olmesartan50 
monotherapy.
Two other studies have evaluated the efficacy of 
  olmesartan/amlodipine-based titration regimens in patients 
with hypertension. The BP-CRUSH (Blood Pressure Con-
trol in All Subgroups with Hypertension) trial was a study 
that evaluated rates of BP goal achievement in patients who 
responded inadequately to antihypertensive monotherapy and 
were switched to olmesartan/amlodipine-based therapy.51 The 
AZTEC (AZOR Trial Evaluating Blood Pressure Reduction 
and Control) study used ABPM to determine the efficacy of 
a fixed-dose combination of olmesartan/amlodipine over the 
24-hour dosing interval in patients with hypertension who did 
not respond adequately to amlodipine monotherapy.52
Only treatment regimens involving olmesartan/amlo-
dipine dosages approved for use in Europe are reviewed here 
with regard to the results obtained in the overall population 
in each study, respectively.
COACH trial
The COACH trial was a multicenter, randomized, double-
blind, placebo-controlled study with a factorial design.46 
Eligible patients were aged $18 years, were naïve to antihy-
pertensive therapy or underwent a 2-week washout period, 
and had a seated DBP (SeDBP) of 95–120 mmHg. Patients 
(n = 1940) were randomized to eight weeks of olmesartan 
monotherapy (10, 20 or 40 mg/day), amlodipine mono-
therapy (5 or 10 mg/day), each possible combination of the 
corresponding olmesartan and amlodipine doses, or placebo. 
The primary endpoint was the change from baseline in mean 
trough SeDBP (measured before taking the daily dose of study 
medication) after eight weeks of treatment in the intent-to-
treat (ITT) population (patients with a BP measurement at 
baseline and at least one BP measurement after taking at least 
one dose of study medication) with   last-observation-carried
-forward (LOCF) imputation.   Secondary endpoints included 
change from baseline in seated SBP (SeSBP), and the propor-
tion of patients achieving the BP target (,140/90 mmHg for 
patients with uncomplicated hypertension; ,130/80 mmHg 
for patients with diabetes). BP was recorded at weeks 2, 4, 6 
and 8 respectively.
A total of 1923 patients were included in the primary 
efficacy analysis, of which 1689 completed the 8-week 
treatment period. All combination and monotherapy dosages 
and placebo were associated with statistically significant 
reductions in SeDBP from baseline to week 8 (P , 0.001) 
(Table 1). The reductions in SeDBP at week 8 seen with each 
monotherapy increased as the dosage of monotherapy rose. 
The combinations of olmesartan/amlodipine also produced 
dose-dependent reductions in SeDBP at week 8, and these 
were significantly greater than those achieved with the 
equivalent doses of olmesartan or amlodipine monotherapy 
(P , 0.001). Changes in SeSBP from baseline to week 8 
  followed a similar pattern to the changes in SeDBP (Table 1). 
The largest reductions in SeDBP and SeSBP were achieved 
after two weeks of active treatment (Figure 1). Thus, about 
85% of the maximum BP reductions observed at the end of 
the 8-week treatment period had been observed after two 
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Figure 1 Mean change in seated systolic blood pressure (SeSBP) from baseline to 
weeks 2, 4, 6 and 8 with olmesartan (OLM) and amlodipine (AML) monotherapy and 
olmesartan/amlodipine combination therapy.
Notes: Based upon data presented by Chrysant et al.46,47 For clarity, some dosages 
and combinations have been omitted from this Figure.
Table 1 The COACH trial – change in seated diastolic blood 
pressure  (SeDBP)  and  seated  systolic  blood  pressure  (SeSBP) 
from baseline to week 8 in the intent-to-treat population (last 
observation carried forward)46
Treatment  
group
No. of  
patients
Mean (SD)  
change in  
SeDBP, mmHg
Mean (SD)  
change in  
SeSBP, mmHg
Olmesartan
  10 mg 160 -8.3 (9.28)** -11.5 (15.23)**
  20 mg 159 -9.2 (9.73)** -13.8 (15.90)**
  40 mg 160 -10.2 (10.69)** -16.1 (16.58)**
Amlodipine
  5 mg 161 -9.4 (8.25)** -14.9 (14.95)**
  10 mg 163 -12.7 (8.25)** -19.7 (16.52)**
Olmesartan/amlodipine
  20 mg/5 mg 160 -14.0 (9.07)** -23.6 (14.86)**
  40 mg/5 mg 157 -15.5 (8.15)** -25.4 (14.70)**
  40 mg/10 mg 161 -19.0 (8.90)** -30.1 (15.91)**
Placebo 160 -3.1 (10.67)** -4.8 (18.70)*
Notes: *P , 0.05; **P , 0.001.
Abbreviation: SD, standard deviation.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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weeks of treatment (Figure 1).47 The benefits of combination 
therapy were observed irrespective of baseline hypertension 
stage.48 Furthermore, prior use of antihypertensive agents did 
not appear to affect efficacy.
Significantly greater proportions of patients receiving 
olmesartan/amlodipine achieved the BP target at week 8 
than patients receiving monotherapy (Table 2). The propor-
tions of patients reaching the BP goal were 42.5%, 51.0% 
and 49.1% for olmesartan/amlodipine 20/5 mg, 40/5 mg and 
40/10 mg, respectively.
At the end of the 8-week randomized phase of the 
COACH trial, 1684 patients entered a 44-week open-
label extension period in which they received olmesartan/
amlodipine 40/5 mg once-daily initially.53 Uptitration to 
olmesartan/amlodipine 40/10 mg, followed by addition of 
HCTZ 12.5 mg and then 25 mg, was permitted if patients 
did not achieve the BP goal. Back-titration was also possible. 
Mean BP decreased from 164/102 mmHg at baseline to 
131/82 mmHg at the end of this open-label extension period, 
while overall 66.7% of patients achieved the BP goal.
A total of 525 patients remained on olmesartan/  amlodipine 
40/5 mg throughout the extension period, and 80.0% of 
these achieved the BP goal. Uptitration to   olmesartan/
amlodipine 40/10 mg alone was necessary in 378 patients, of 
whom 70.6% achieved the BP goal. Addition of HCTZ at a 
dose of 12.5 mg/day (n = 287) or 25 mg/day (n = 419) resulted 
in 66.6% and 46.3% of the respective patients achieving their 
BP goal. Thus, treatment with olmesartan/amlodipine and 
up-titration as necessary, with or without HCTZ, allowed 
the majority of patients to achieve BP control.
Trial in patients with inadequate response   
to amlodipine monotherapy
This randomized, double-blind, multicenter study evaluated the 
efficacy of olmesartan/amlodipine in patients aged $18 years 
with moderate-to-severe hypertension who failed to respond 
adequately to amlodipine monotherapy.49 Patients received 
open-label amlodipine 5 mg/day monotherapy for eight 
weeks. At the end of the monotherapy phase, patients with 
BP $ 140/90 mmHg were randomized to eight weeks of 
double-blind daily treatment with amlodipine 5 mg plus placebo 
or olmesartan/amlodipine 10/5 mg, 20/5 mg or 40/5 mg. At the 
end of the double-blind period, patients who had achieved the 
target BP of ,140/90 mmHg continued on randomized therapy 
for a further eight weeks. Patients with BP $ 140/90 mmHg 
had their medication uptitrated to olmesartan/amlodipine 
20/5 mg, 40/5 mg or 40/10 mg during this period.
The primary endpoint was the change in mean trough 
SeDBP from the end of the open-label run-in period (baseline) 
to the end of double-blind treatment (week 8) in the ITT popu-
lation (defined as in the COACH trial) with LOCF imputation. 
Key secondary endpoints included the mean changes in trough 
SeDBP (baseline to week 4) and trough SeSBP (baseline to 
weeks 4 and 8), and the additional mean changes in SeDBP 
and SeSBP that occurred with further double-blind treatment 
(week 8 to week 16). The proportions of patients achieving 
the BP goal (defined as in the COACH trial) at weeks 8 and 
16 of the double-blind phase were assessed.
A total of 755 patients were randomized to double-blind 
treatment, and 746 were included in the primary efficacy 
analysis. Compared with patients who were randomized 
to continue with amlodipine 5 mg, patients who were ran-
domized to each olmesartan/amlodipine regimen showed 
  significantly greater reductions in mean SeDBP from baseline 
to week 8 of the double-blind phase. The additional reduc-
tions in SeDBP achieved with olmesartan/amlodipine 20/5 
and 40/5 mg compared with amlodipine 5 mg were 3.7 and 
3.8 mmHg respectively (P , 0.0001) (Figure 2). Patients 
receiving olmesartan/amlodipine also experienced greater 
reductions in mean SeSBP from baseline to week 8 of the 
double-blind phase. The additional reductions in SeSBP 
achieved with olmesartan/amlodipine 20/5 and 40/5 mg 
compared with amlodipine 5 mg were 5.8 and 7.1 mmHg 
respectively (P , 0.0001) (Figure 2). All treatment regimens 
demonstrated a reduction in mean SeDBP and SeSBP after 
four weeks of double-blind treatment. In the second half of 
the double-blind phase, patients who had not achieved BP 
control had their treatment uptitrated and showed further 
significant increases in BP reduction by the end of this   second 
Table  2  The  COACH  trial  –  patients  achieving  the  blood 
pressure target (,140/90 mmHg for patients with uncomplicated 
hypertension; ,130/80 mmHg for patients with diabetes) after 
eight weeks of treatment (last observation carried forward)46
Treatment group  No (%)
Olmesartan
  10 mg (n = 160) 32 (20.0)
  20 mg (n = 159) 42 (26.4)
  40 mg (n = 160) 58 (36.3)
Amlodipine
  5 mg (n = 161) 34 (21.1)
  10 mg (n = 163) 53 (32.5)
Olmesartan/amlodipine
  20 mg/5 mg (n = 160) 68 (42.5)*,†
  40 mg/5 mg (n = 157) 80 (51.0)*,†
  40 mg/10 mg (n = 161) 79 (49.1)*,†
Placebo (n = 160) 14 (8.8)
Notes: *P , 0.005 vs olmesartan monotherapy at the same dosage; †P , 0.001 vs 
amlodipine monotherapy at the same dosage.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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8-week treatment phase. Uptitration of amlodipine 5 mg to 
olmesartan/amlodipine 20/5 mg, olmesartan/amlodipine 
20/5 to 40/5 mg, and olmesartan 40/5 to 40/10 mg resulted 
in further mean reductions of SBP (Figure 3) and DBP: -8.2, 
-6.2 and -8.2 mmHg respectively.
The proportion of patients reaching their BP goal at week 8 of 
double-blind treatment was significantly higher for olmesartan/
amlodipine 20/5 mg (54%) and 40/5 mg (51%) compared with 
amlodipine monotherapy (30%) (P , 0.0001).   Continuation 
of combination therapy for an additional eight weeks, without 
uptitration, resulted in BP goal achievement by over 70% of 
patients. Uptitration of medication resulted in an additional 
36%–47% of patients achieving their BP goal. Overall, 469 of 
746 patients (63%) achieved their BP goal at the end of 16 weeks 
of double-blind therapy, with or without uptitration.
This study also included ABPM measurements at the start 
and end of the first 8-week, double-blind phase, and after the 
additional eight weeks of randomized treatment with upti-
tration as necessary. During the first 8-week, double-blind 
period, each dose of olmesartan/amlodipine significantly 
reduced 24-hour, daytime and night-time DBP and SBP, 
compared with amlodipine 5 mg plus placebo.54,55 In patients 
who did not achieve their BP goal with their initial dosage 
of combination therapy, uptitration led to further reductions 
in 24-hour, daytime and night-time BP.56 Taken together, the 
ABPM measurements were in agreement with the scheduled 
office BP measurements. Moreover, the detected BP reduc-
tions were consistent over the 24-hour dosing interval.55
Patients who completed the 16 weeks of double-blind 
combination therapy entered a 28-week, open-label phase 
in which they received olmesartan/amlodipine 40/5 mg 
once daily (n = 691).57 After 4, 10 and 19 weeks in the 
open-label phase, patients with inadequately controlled 
BP had their doses increased in a stepwise manner, with 
addition of HCTZ as necessary, to: olmesartan/amlodipine 
40/10 mg; olmesartan/amlodipine/HCTZ 40/10/12.5 mg; and 
  olmesartan/amlodipine/HCTZ 40/10/25 mg. The majority of 
patients remained on olmesartan/amlodipine 40/5 mg with-
out uptitration, and 74.3% of these patients achieved their 
BP goal. Additional patients achieved with each successive 
uptitration. Overall, 66.9% of patients achieved their BP goal 
during this 28-week, open-label phase. Analysis of the final 
reductions in SBP, observed at the end of the overall active 
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eight weeks of randomized, double-blind, uptitrated treatment.49
Notes:  †Uptitration of  non-responders:  patients  whose  BP  was  not  adequately 
controlled  (SeDBP  $90  mmHg  and  SeSBP  $140  mmHg)  during  randomized 
treatment in Period ii.
Abbreviations: AML, amlodipine; OLM, olmesartan; SeSBP, seated systolic blood 
pressure.
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treatment period of 52 weeks, revealed that SBP reductions 
were related to the initial SBP level at the start of the study.58 
Thus, patients with higher baseline SBP levels achieved 
larger reductions in SBP (Figure 4). Furthermore, despite 
the substantial reductions in BP achieved with olmesartan/
amlodipine in this study, it is notable that the incidence of 
treatment-related hypotension was very low. Among the 
578 patients who completed the 28-week, open-label phase, 
and received olmesartan/  amlodipine 40/5 mg or 40/10 mg 
without the addition of HCTZ, there were four reports 
of   hypotension (0.7%), all involving patients receiving 
  olmesartan/  amlodipine 40/5 mg.
Trial in patients with inadequate response   
to olmesartan monotherapy
Findings of a multicenter, randomized, double-blind trial con-
ducted in patients aged $18 years with moderate-to-severe 
hypertension demonstrated that the addition of amlodipine to 
olmesartan lowered BP to a greater extent and enabled more 
patients to achieve their BP goal compared with olmesartan 
monotherapy.50
After eight weeks of randomized, double-blind treatment, 
the additional reduction in SeDBP and SeSBP achieved with 
olmesartan/amlodipine 20/5 mg compared with olmesar-
tan 20 mg monotherapy was 2.7 mmHg (P = 0.0006) and 
5.3 mmHg (P , 0.0001), respectively. Furthermore, the 
proportion of patients achieving their BP goal was signifi-
cantly higher for olmesartan/amlodipine 20/5 mg (44.5%) 
compared with olmesartan 20 mg monotherapy (28.5%) 
(P = 0.0011).
AZTEC and BP-CRUSH – efficacy of  
amlodipine/olmesartan-based titration  
regimens
AZTEC and BP-CRUSH are postregistration studies designed 
to obtain further information on the efficacy of olmesartan/
amlodipine, both of which used tight BP control and forced 
titration regimens.
The AZTEC study was an open-label, multicenter, 
single-arm, dose-titration study in 185 patients with hyperten-
sion, consisting of a 3–4-week placebo run-in period and a 
12-week active treatment period.52 Initially, patients received 
amlodipine 5 mg/day. If SeBP remained $120/80 mmHg, 
as assessed using conventional office-based BP measure-
ments, medication was uptitrated at 3-weekly intervals to 
olmesartan/amlodipine 20/5, 40/5 and 40/10 mg. The change 
from baseline in mean 24-hour ambulatory SBP/DBP at 
week 12 (the primary endpoint), as assessed by ABPM, 
was –21.4/–12.7 mmHg (P , 0.0001 vs baseline). The 
reduction in BP was consistent across the 24-hour dosing 
interval. The proportions of patients achieving the prespeci-
fied mean 24-hour ambulatory BP target of ,130/80 mmHg 
was 70.9%. Dose-dependent reductions in office-based SeBP 
from   baseline were observed with the stepwise olmesartan/
amlodipine treatment algorithm, with the largest reductions 
in SeBP seen with the olmesartan/amlodipine 40/10 mg 
combination for which, cumulatively, 76.8% of patients 
achieved a SeBP goal of ,140/90 mmHg.
BP-CRUSH was an open-label, multicenter, single-
arm, dose-titration study with a 20-week active-treatment 
period, the aim of which was to demonstrate that patients 
with hypertension who had previously failed to achieve 
BP control on monotherapy were able to achieve their 
BP goal with an olmesartan/amlodipine-based treatment 
regimen, which also included the addition of HCTZ.59 On 
day 1, patients (n = 999) were switched from antihyper-
tensive monotherapy to olmesartan/amlodipine 20/5 mg. 
If BP remained .120/70 mmHg, medication was upti-
trated at 4-weekly intervals to olmesartan/amlodipine 
40/5 mg, olmesartan/amlodipine 40/10 mg, olmesartan/
amlodipine/HCTZ 40/10/12.5 mg and olmesartan/amlo-
dipine/HCTZ 40/10/25 mg. The primary efficacy end-
point, the proportion of patients achieving the SeBP goal 
(,140 mmHg; ,130 mmHg for patients with diabetes) 
at the end of 12 weeks of olmesartan/amlodipine therapy, 
was 75.8%. Mean changes from baseline in BP at the end 
of each titration period ranged from -14.2/-7.7 mmHg for 
olmesartan/amlodipine 20/5 mg to -25.1/-13.7 mmHg 
for olmesartan/amlodipine/HCTZ 40/10/25 mg. The BP 
goal (,140/90 mmHg) was achieved by 90.3% of patients 
who received olmesartan/amlodipine/HCTZ 40/10/25 mg 
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 ( Figure 5).51 ABPM measurements taken in a subgroup of 
patients (n = 243) at baseline and 12 and 20 weeks after treat-
ment showed that BP reductions were sustained throughout 
the 24-hour dosing interval.51
Tolerability of olmesartan/amlodipine
Olmesartan/amlodipine was generally well tolerated in clini-
cal trials in patients with mild to severe hypertension. In the 
COACH trial, 521 of the 1940 randomized patients (26.9%) 
experienced a drug-related treatment-emergent adverse event 
(TEAE), with an overall incidence of 19.9% to 33.1% across 
the active-treatment groups receiving approved dosages and 
29.6% for placebo-treated patients.46 The majority of these 
adverse events were mild in severity. Peripheral edema was 
the most common TEAE, affecting 385 of the 1940 patients 
(19.8%). Other commonly reported TEAEs were headache 
(130/1940 [6.7%]), dizziness (76/1940 [3.9%]) and fatigue 
(62/1940 [3.2%]), with no consistent differences between 
the active-treatment groups. Headache occurred most fre-
quently in the placebo group (23/162 [14.2%]). Overall, 3.8% 
(74/1940) of patients were withdrawn from the trial because 
of drug-related TEAEs. The only serious drug-related TEAE 
was a nonfatal cerebrovascular accident occurring in a patient 
receiving olmesartan 20 mg/day, in whom BP was not fully 
controlled. Hypotension was reported in 0.5% (9/1940) of 
patients across the treatment groups. Seven patients had 
drug-related hypotension, of which two were withdrawn 
from the trial because of moderate or severe hypotension. In 
the 44-week open-label extension of the COACH trial, the 
adverse event profile was similar to that observed during the 
double-blind phase.
In the trials comparing olmesartan/amlodipine with the 
respective monotherapies, drug-related TEAEs were reported 
in 5.3%–7.7% of patients receiving approved dosages of 
olmesartan/amlodipine compared with 7.4% and 8.9% of 
patients receiving amlodipine or olmesartan monotherapy, 
respectively.49,50 Few patients receiving combination therapy 
in either trial discontinued due to a drug-related TEAE, and no 
serious drug-related TEAEs were observed in either trial.
Peripheral edema represents a common side effect of 
CCBs such as amlodipine, because these drugs may increase 
capillary pressure in peripheral tissues by inducing precapil-
lary vasodilation of resistance arteries.60 Peripheral edema 
may be ameliorated by coadministration of an ARB or ACEI, 
as these agents may lower capillary pressures by decreasing 
postcapillary resistance in veins.46 The COACH trial assessed 
patients specifically for peripheral edema, rating its presence 
on a 5-point severity scale at all scheduled clinic visits.46,53 
At baseline, 264 of the 1940 randomized patients (13.6%) 
had peripheral edema, which was predominantly graded as 
mild.46 During the 8-week, randomized, double-blind treat-
ment phase, the frequency of edema was greatest among 
patients receiving amlodipine 10 mg monotherapy (60/163 
[36.8%]), and affected 12.3% (20/162) of patients receiving a 
placebo. As expected, the frequency of peripheral edema was 
lower in the olmesartan/amlodipine 40/10 mg group (38/162 
[23.5%]) than in the amlodipine 10 mg group (P = 0.011). 
Most cases of edema were mild or moderate in severity. 
Severe edema occurred in one patient (0.6%) in the amlo-
dipine 5 mg group, two patients (1.2%) in the amlodipine 
10 mg group and one patient (0.6%) in the olmesartan/
amlodipine 40/10 mg group. Edema was also reported in the 
trials comparing   olmesartan/amlodipine with the respective 
monotherapies, but the   frequencies were lower than in the 
COACH trial.49,50
Conclusion
In randomized, double-blind trials, olmesartan/amlodipine 
has demonstrated greater efficacy than the respective 
monotherapies in reducing BP, including a reduction within 
two weeks of initiation in the COACH trial, and achiev-
ing their BP goals, including over 24 hours, in patients 
with moderate-to-severe hypertension who had responded 
inadequately to olmesartan or amlodipine monotherapy. Up 
to 54% of patients who had failed to respond adequately 
to olmesartan or amlodipine monotherapy achieved their 
BP goal during eight weeks of treatment with olmesartan/
amlodipine. Uptitration of olmesartan/amlodipine provided 
additional BP reductions, allowing even more patients to 
achieve their BP goal, while the incidence of hypotension 
remained very low. Furthermore, treat-to-target studies have 
demonstrated the power of olmesartan/amlodipine-based 
treatment in achieving high BP goal rates. Olmesartan/
amlodipine was generally well tolerated over short- and 
long-term therapy and this observation was not affected 
by uptitration. Peripheral edema was significantly less 
common with olmesartan/amlodipine 40/10 mg than with 
amlodipine 10 mg monotherapy. In Europe, a fixed-dose 
combined olmesartan/amlodipine formulation is available 
in three dosages (20/5, 40/5 and 40/10 mg), allowing flex-
ible dosing and uptitration.
Acknowledgment
Editorial assistance was provided by Phil Jones and Amy 
McCallum (inScience Communications, a Wolters Kluwer 
business, Chester, UK), and funded by Daiichi Sankyo. Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
191
Olmesartan/amlodipine in hypertension management
Disclosure
The author has received honoraria for lectures and consul-
tancy fees from Daiichi Sankyo, Berlin-Chemie AG, and 
Menarini International.
References
  1.  Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected 
major risk factors and global and regional burden of disease. Lancet. 
2002;360(9343):1347–1360.
  2.  World Health Organization. Reducing Risks, Promoting Healthy Life. 
The World Health Report. Available at: http://www.who.int/whr/2002/
en/whr02_en.pdf. Accessed September 17, 2008.
  3.  Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. 
Global burden of hypertension: analysis of worldwide data. Lancet. 
2005;365(9455):217–223.
  4.  Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, aware-
ness, treatment, and control of hypertension among United States adults 
1999–2004. Hypertension. 2007;49(1):69–75.
  5.  Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence 
and blood pressure levels in 6 European countries, Canada, and the 
United States. JAMA. 2003;289(18):2363–2369.
  6.  Smith DH. Comparison of angiotensin II type 1 receptor antago-
nists in the treatment of essential hypertension. Drugs. 2008;68(9): 
1207–1225.
  7.  Kannel WB. Blood pressure as a cardiovascular risk factor: prevention 
and treatment. JAMA. 1996;275(20):1571–1576.
  8.  Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage 
renal disease in men. N Engl J Med. 1996;334(1):13–18.
  9.  Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of   European 
guidelines on hypertension management: a European Society 
of Hypertension Task Force document. J Hypertens. 2009;27: 
2121–2158.
  10.  ALLHAT Officers and Coordinators for the ALLHAT Collaborative 
Research Group. Major outcomes in high-risk hypertensive patients ran-
domized to angiotensin-converting enzyme inhibitor or calcium channel 
blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23): 
2981–2997.
  11.  Dolor RJ, Yancy WS Jr, Owen WF, et al. Hypertension Improvement Project 
(HIP): study protocol and implementation challenges. Trials. 2009;10:13.
  12.  Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment 
trials of hypertension: improving the estimate of therapeutic benefit. 
J Hum Hypertens. 1996;10(1):1–8.
  13.  Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated 
with antihypertensive therapies used as first–line agents. A systematic 
review and meta-analysis. JAMA. 1997;277(9):739–745.
  14.  SHEP Cooperative Research Group. Prevention of stroke by 
  antihypertensive drug treatment in older persons with isolated   systolic 
  hypertension. Final results of the Systolic Hypertension in the Elderly 
Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 
265(24):3255–3264.
  15.  Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treat-
ment, treatment intensification, and control in Western Europe and the 
United States. Arch Intern Med. 2007;167(2):141–147.
  16.  Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment 
and control in five European countries, Canada, and the United States. 
Hypertension. 2004;43(1):10–17.
  17.  Cushman WC, Basile J. Achieving blood pressure goals: why aren’t 
we? J Clin Hypertens (Greenwich). 2006;8(12):865–872.
  18.  Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern 
Med. 2001;135(9):825–834.
  19.  Spranger CB, Ries AJ, Berge CA, Radford NB, Victor RG. Identifying 
gaps between guidelines and clinical practice in the evaluation and treat-
ment of patients with hypertension. Am J Med. 2004;117(1): 14–18.
  20.  Kreutz R. Pharmacogenetics of antihypertensive drug response.   
Curr Hypertens Rep. 2004;6(1):15–20.
  21.  Neutel JM. Low-dose antihypertensive combination therapy: its 
  rationale and role in cardiovascular risk management. Am J Hypertens. 
1999;12(8 Pt 2):73S–79S.
  22.  Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination 
therapy versus monotherapy in reducing blood pressure:   meta-analysis 
on 11,000 participants from 42 trials. Am J Med. 2009;122(3): 
290–300.
  23.  Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular 
events with an antihypertensive regimen of amlodipine adding per-
indopril as required versus atenolol adding bendroflumethiazide as 
required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood 
Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised 
controlled trial. Lancet. 2005;366(9489):895–906.
  24.  Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine 
or hydrochlorothiazide for hypertension in high-risk patients. N Engl 
J Med. 2008;359(23):2417–2428.
  25.  Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients 
at high cardiovascular risk treated with regimens based on valsartan 
or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426): 
2022–2031.
  26.  Cushman WC, Evans GW, Byington RP, et al. Effects of intensive 
blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 
362(17):1575–1585.
  27.  Gradman AH, Basile JN, Carter BL, et al. Combination therapy in 
hypertension. J Am Soc Hypertens. 2010;4(2):90–98.
  28.  Bramlage P. Fixed-dose combinations of renin-angiotensin blocking 
agents with calcium channel blockers or hydrochlorothiazide in the 
treatment of hypertension. Expert Opin Pharmacother. 2009;10(11): 
1755–1767.
  29.  Schmieder RE. The role of fixed-dose combination therapy with drugs 
that target the renin-angiotensin system in the hypertension paradigm. 
Clin Exp Hypertens. 2010;32(1):35–42.
  30.  Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness 
of fixed-dose combinations of antihypertensive agents: a meta-analysis. 
Hypertension. 2010;55(2):399–407.
  31.  Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combi-
nation treatment with blood pressure lowering drugs: analysis of 354 
randomised trials. Br Med J. 2003;326(7404):1427.
  32.  Frishman WH, Ram CV , McMahon FG, et al. Comparison of amlodipine 
and benazepril monotherapy to amlodipine plus benazepril in patients 
with systemic hypertension: a randomized, double-blind, placebo-
controlled, parallel-group study. The Benazepril/Amlodipine Study 
Group. J Clin Pharmacol. 1995;35(11):1060–1066.
  33.  Kuschnir E, Acuna E, Sevilla D, et al. Treatment of patients with 
essential hypertension: amlodipine 5 mg/benazepril 20 mg compared 
with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther. 
1996;18(6):1213–1224.
  34.  Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in 
patients at high risk for vascular events. N Engl J Med. 2008;358(15): 
1547–1559.
  35.  Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. 
Angioedema incidence in US veterans initiating angiotensin-converting 
enzyme inhibitors. Hypertension. 2008;51(6):1624–1630.
  36.  National Institute for Health and Clinical Excellence. Hypertension: 
Management of hypertension in adults in primary care. Available 
at: http://www.nice.org.uk/nicemedia/live/10986/30114/30114.pdf. 
Accessed June 9, 2010.
  37.  Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive 
activity of angiotensin II AT1 receptor antagonists: a systematic review 
of studies with 24 h ambulatory blood pressure monitoring. J Hypertens. 
2007;25(7):1327–1336.
  38.  Coltamai L, Maillard M, Simon A, Vogt B, Burnier M. Comparative 
vascular and renal tubular effects of angiotensin II receptor blockers 
combined with a thiazide diuretic in humans. J Hypertens. 2010;28(3): 
520–526.Vascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
192
Kreutz
  39.  Hasler C, Nussberger J, Maillard M, Forclaz A, Brunner HR, Burnier M. 
Sustained 24-hour blockade of the renin-angiotensin system: a high 
dose of a long-acting blocker is as effective as a lower dose combined 
with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther. 
2005;78(5):501–507.
  40.  Jones MR, Sealey JE, Laragh JH. Effects of angiotensin receptor 
blockers on ambulatory plasma renin activity in healthy, normal sub-
jects during unrestricted sodium intake. Am J Hypertens. 2007;20(8): 
907–916.
  41.  Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of 
olmesartan medoxomil and candesartan cilexetil assessed by 24-hour 
ambulatory blood pressure monitoring in patients with essential 
  hypertension. Clin Drug Invest. 2003;23(7):419–430.
  42.  Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative 
efficacy of olmesartan, losartan, valsartan, and irbesartan in the control 
of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(5): 
283–291, 318.
  43.  Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pres-
sure monitoring to assess antihypertensive efficacy: a comparison of 
olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. 
Am J Cardiovasc Drugs. 2005;5(1):41–50.
  44.  Scott LJ, McCormack PL. Olmesartan medoxomil: a review of 
its use in the management of hypertension. Drugs. 2008;68(9): 
1239–1272.
  45.  Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacologi-
cal properties and therapeutic use in cardiovascular disease. Drugs. 
1995;50(3):560–586.
  46.  Chrysant S, Melino M, Karki S, Lee J, Heyrman R. The combination 
of olmesartan medoxomil and amlodipine besylate in controlling 
high blood pressure: COACH, a randomized, double-blind, placebo-
controlled, 8-week factorial efficacy and safety study. Clin Ther. 
2008;30(4):587–604.
  47.  Chrysant S, Melino M, Karki S, Lee J, Heyrman R. Onset of antihy-
pertensive effect in patients with mild-to-severe hypertension treated 
with a combination of amlodipine besylate and olmesartan medoxomil 
compared with component monotherapy and placebo. J Clin Hypertens. 
2008a;26:378 Suppl 1:378.
  48.  Oparil S, Lee J, Karki S, Melino M. Subgroup analyses of an efficacy and 
safety study of concomitant administration of amlodipine besylate and 
olmesartan medoxomil: evaluation by baseline hypertension stage 
and prior antihypertensive medication use. J Cardiovasc Pharmacol. 
2009;54(5):427–436.
  49.  Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olm-
esartan medoxomil combined with amlodipine in patients with moderate 
to severe hypertension after amlodipine monotherapy: a randomized, 
double-blind, parallel-group, multicentre study. Clin Drug Investig. 
2009;29(1):11–25.
  50.  Barrios V , Brommer P, Haag U, Calderon A, Escobar C. Olmesartan 
medoxomil plus amlodipine increases efficacy in patients with 
moderate-to-severe hypertension after monotherapy: a randomized, 
double-blind, parallel-group, multicentre study. Clin Drug Investig. 
2009;29(7):427–439.
  51.  Weir MR, Hsueh WA, Nesbitt SD, et al. Effects on BP control of 
amlodipine (AML)/olmesartan medoxomil (OM), with or without 
hydrochlorothiazide (HCTZ), in patients not controlled by prior 
antihypertensive monotherapy (late breaker at the American Society 
of Hypertension 25th Annual Scentific Meeting, New York). J Clin 
Hypertens (Greenwich). 2010;12(7):536.
  52.  Punzi H, Neutel JM, Kereiakes DJ, et al. Efficacy of amlodipine and 
olmesartan medoxomil in patients with hypertension: the AZOR Trial 
Evaluating Blood Pressure Reductions and Control (AZTEC) study. 
Ther Adv Cardiovasc Dis. 2010;4(4):209–221.
  53.  Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R. Efficacy 
and safety of long-term treatment with the combination of amlodipine 
besylate and olmesartan medoxomil in patients with hypertension.   
J Clin Hypertens (Greenwich). 2009;11(9):475–482.
  54.  Heagerty AM, Laeis P, Haag U. Olmesartan medoxomil/amlodipine 
(OLM/AML) provides 24-hour antihypertensive efficacy – additional 
effect by uptitration in patients with moderate-to-severe hypertension. 
J Hypertens. 2009;27 Suppl 4:S283.
  55.  Parati G, Bilo G. Olmesartan medoxomil/amlodipine (OLM/AML) 
improves blood pressure (BP) control throughout 24 hours   compared with 
AML monotherapy in patients with moderate-to-severe   hypertension.   
J Hypertens. 2010;28:e111.
  56.  Heagerty AM, Laeis P, Haag U. Olmesartan medoxomil/amlodipine 
(OLM/AML) provides 24-hour antihypertensive efficacy – additional 
effect by uptitration in patients with moderate-to-severe hypertension. 
J Hypertens. 2009;27 Suppl 4:S283.
  57.  Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care 
regimen using olmesartan medoxomil, amlodipine and hydrochlorothi-
azide in patients with moderate-to-severe hypertension: an open-label, 
  long-term study. Clin Drug Investig. 2009;29(6):381–391.
  58.  Mourad JJ, Le Jeune S. Effective systolic blood pressure reduction 
with olmesartan medoxomil/amlodipine combination therapy: post 
hoc analysis of data from a randomized, double-blind, parallel-group, 
multicentre study. Clin Drug Investig. 2009;29(6):419–425.
  59.  Weir M, Hsueh WA, Nesbitt SD, et al. Effects on BP control of 
  amlodipine (AML)/olmesartan medoxomil (OM), with or without 
hydrochlorothiazide (HCTZ), in patients not controlled by prior anti-
hypertensive monotherapy. 2010: Presented as a late breaker at the 
American Society of Hypertension 25th Annual Scentific Meeting and 
Exposition 2010: New York.
  60.  Opie LH. Pharmacological differences between calcium antagonists. 
Eur Heart J. 1997;18 Suppl A:A71–A79.